Valencia, Spain and Boston, MA, and Leiden, The Netherlands, March 31, 2022 – Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems for active pharmaceutical ingredients (APIs). The LACDR team will be led by Prof. Matthias Barz, a pioneer in polypept(o)ids, and expert in functional nanoparticles for biomedical applications.

Under this collaboration, PTS and LACDR will establish novel methodologies for the synthesis of functional polypept(o)ides and nanoparticles allowing for GMP production of these materials.

“This collaboration will allow PTS to provide the most advanced drug delivery technologies, leading to greater efficiency, targeting, and safety profile of novel therapeutics,” said Vicent Nebot, Chief Technical Officer of PTS. “We are excited to be working with Prof. Matthias Barz, a leading expert in polypept(o)ids synthesis, characterization, and functionalization strategies essential for the design of API delivery systems.”

This collaboration will enable PTS to broaden and improve the scope of the current tailored polysarcosine- and polypept(o)ide-based technological solutions offered to partners and customers.

“We look forward to collaborating with PTS to make polysarcosine and polypept(o)ide-based materials and systems available for their pharmaceutical client,” said Prof. Barz. “These novel materials will combine advanced features of functionality, high biocompatibility, and tunable degradability.”

About Polypeptide Therapeutic Solutions

Polypeptide Therapeutic Solutions (PTS) is a leading GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications including mRNA, DNA, cell therapies, gene therapies, biologics, vaccines, and small molecule therapies. The PTS team of expert biochemists and polymeric material scientists are critical partners in the drug development and commercialization processes of some of the leading therapeutics companies in the world. The company offers contract development and manufacturing services including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill/finish services. Learn more at

About LACDR and the Barz Lab

The Leiden Academic Centre for Drug Research (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development. It is ranked 11 globally by 2021 QS University Ranking in Pharmaceutical sciences underlining its global leadership position.

Within LACDR the Barz Lab focusses on the development of systems for the controlled delivery of biotherapeutics. They have introduced the term polypept(o)ides in 2014, which describes copolymers combining polypeptoids, in particular polysarcosine, with functional polypeptides. Besides, the group of Matthias Barz are world leader in the development of polysarcosine based lipids, which show reduced immunogenicity compared to PEGylated counterparts in liposomes and mRNA containing lipid nanoparticles (LNPs). Learn more at